XVIR-110: ultra-long-lasting injectable HIV prevention
Official title: XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies
Funded at Exavir Therapeutics INC. · NIH-11137684 · Data updated 2026-11-12
Developing a single injectable medicine that could protect adults and adolescents at risk of HIV for many months with fewer clinic visits.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Exavir Therapeutics INC. NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project start | August 17, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI179564-03 |
| Project ID | NIH-11137684 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and adolescents at risk of acquiring HIV who are candidates for HIV pre-exposure prophylaxis (PrEP) would be the intended participants.
✕Less likely to help
People already living with HIV, those not at risk of HIV, or those with allergies or contraindications to integrase inhibitors or injectable treatments may not benefit from this approach.
What this research studies
This project is creating an ultra-long-lasting injectable form of an HIV prevention drug that slowly releases medicine over a long period using a nanoformulated prodrug. The team is doing the lab and animal safety, dosing, and drug-release studies needed to move toward human testing. Their work builds on earlier Phase I–equivalent results to try to extend how long one dose protects someone. The aim is to make PrEP easier to stick with and reduce new HIV infections and drug resistance.
Why it matters
Potential benefit: If successful, one injection could provide months of HIV protection, improving adherence and lowering the chance of new infections.
How similar studies have gone: Long-acting injectable PrEP (for example, cabotegravir) has shown success, but ultra-long-acting nanoformulated prodrugs are a newer approach with less clinical experience.
Where this research is happening
-
Exavir Therapeutics INC.
San Francisco, United States Active
Researchers
- Principal investigator: Kearney, Brian — Exavir Therapeutics INC.
- Study coordinator: Kearney, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.